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Abstract 
Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) has been 
reported to be associated with acute coronary syndrome (ACS), but its association with obesity has 
not been elucidated. In this study, we examined whether weight reduction would reduce the serum 
levels of sLOX-1 in a 12-week weight-reduction intervention. Thirty-eight over-weight middle-aged 
men were enrolled in the study and 32 completed the intervention. The serum level of sLOX-1 was 
measured using a chemiluminescent enzyme-linked immunoassay. Following the intervention 
program, body weight and the serum level of sLOX-1 decreased significantly (-7.5% ± 4.8% and 
-72.1% ± 35.9%, respectively). Changes in serum levels of sLOX-1 were positively correlated with 
changes in body weight (r = 0.54, P = 0.003), body mass index (BMI) (r = 0.57, P = 0.001), body fat 
mass (r = 0.57, P = 0.002), total cholesterol (r = 0.41, P = 0.03), subcutaneous fat area (r = 0.50, P = 
0.007), high sensitive C-reactive protein (hsCRP) (r = 0.56, P = 0.002), leptin (r = 0.47, P = 0.01) 
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and tumor necrosis factor-α (r = 0.32, P = 0.09), but no correlations were observed with fasting 
glycemic related factors (blood glucose, hemoglobin A1c, insulin). Changes in BMI and hsCRP were 
selected as significant predictors of sLOX-1 changes by multiple regression analyses. These results 
suggest that LOX-1 induction may be related to adipocyte metabolism, inflammation, and immune 
response associated with obesity.  5 
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1. Introduction 
Acute coronary syndrome (ACS) is one of the major causes of mortality and morbidity in 
developed countries. Since accurate diagnosis of ACS at the earliest stage can improve the prognosis 
of patients, a sensitive and specific early biomarker for ACS would be desirable. Moreover, oxidized 
low-density lipoprotein (Ox-LDL) and its receptor appear to play key roles in atherogenesis and the 
process of atherosclerotic plaque destabilization, erosion, and rupture, which are the major causes of 
ACS [1,2].  
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Lectin-like oxidized LDL receptor-1 (LOX-1), a type II membrane glycoprotein acting as a 
receptor for Ox-LDL, mediates Ox-LDL induced vascular dysfunction [3–6]. LOX-1 is cleaved from 
the cell surface by certain protease activities, released as soluble LOX-1 (sLOX-1). Circulating 
sLOX-1 levels are elevated in individuals with ACS, reflecting its prominent expression and 
enhanced protease activities in vulnerable atherosclerotic plaques in situ, and those circulating 
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LOX-1 levels can be a useful biomarker for ACS [7,8]. ACS is also thought to involve 
proinflammatory and immune responses [9,10]. Lubrano V et al. [11] have reported sLOX-1 being 
associated with inflammatory markers. Obesity, on the other hand, can be characterized by a state of 
chronic low-grade inflammation [12,13]. Long-term activation of proinflammatory pathways may be 
a mechanism for the development of insulin resistance [14], while serum concentrations of various 
cytokines are increased in obese individuals and may decrease after weight reduction [15-17]. 
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However, the pathophysiological roles of sLOX-1 remain unclear. That is, the relationships 
between circulating sLOX-1 levels and inflammatory factors in obese individuals and the effect of 
weight reduction on circulating sLOX-1 levels are still unknown. Therefore, the aims of this study 
were 1) to assess whether weight reduction affects expression of sLOX-1 and 2) to assess whether 
changes in serum levels of sLOX-1 vary among individuals and whether they are associated with 
changes in anthropometric and metabolic parameters, adipocytokines, proinflammatory cytokines, 
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and high sensitive C-reactive protein (hsCRP) brought about by weight reduction in over-weight 
middle-aged men. 
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2. Methods 
2.1. Subjects 
Thirty-eight Japanese men were recruited through advertisements in a local newspaper. 
Participants were excluded if they had a body mass index (BMI) less than 25 kg/m2; were smokers; 
had concomitant renal, hepatic or cardiac disease; and/or were being treated with drugs that could 
affect the variables of the study. Six subjects were unable to complete the study successfully for 
personal reasons. This left 32 men, aged 32-66 years, to be measured. Assays and measurements 
were carried out at 7days before onset of the intervention and 10days after a 12-week 
weight-reduction intervention. The aim and design of the study were explained to all subjects before 
they gave their written consent. In addition, the study conformed to the principles outlined in the 
Helsinki Declaration and was approved by the Review Board of the University of Tsukuba. 
5 
10 
 
 10
2.2. Dietary and exercise protocol  
All subjects were instructed to have a well-balanced 1680 kcal meal per day during the 12-week 
intervention. Subjects kept daily food diaries during this period and received weekly lectures and 
counseling from skilled dieticians. In addition to diet, subjects performed an exercise program that 
consisted of 36 walking and jogging sessions (three days per week), which were supervised by two 
or three exercise instructors. In the first two months, the exercise program entailed only walking, 
with the target Borg’s scale [18] ranging from 11 (light) to 13 (fairly hard). In the last month, 
subjects performed a combination of a 3.0 km of brisk walking and 1.0 km of middle-intensity 
jogging, with the target Borg’s scale ranging from 13 (fairly hard) to 15 (hard). Subjects measured 
their heart rates by palpation while walking or jogging, and recorded the duration (minutes) and 
intensity (heart rate or the Borg’s scale) of each exercise session. 
5 
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2.3. Clinical variables 
Body weight was measured to the nearest 0.1 kg using a digital scale. Height was measured to 
the nearest 0.1 cm using a wall-mounted stadiometer, while body mass index (BMI) was calculated 
as weight (kg) divided by height squared (m2). A dual-energy X-ray absorptiometry (DXA) machine 
(DPX-NT, Lunar, Madison, Wisconsin, USA) was used to evaluate body composition, which 
consisted of fat tissue and lean soft tissue. Visceral fat area (VFA) and subcutaneous fat area (SFA) 
were measured at the level of the umbilicus (L4-L5) using computed tomography (CT) scans 
(Somatom AR.C, Siemens, Erlangen, Germany), which were performed on subjects in the supine 
position. VFA and SFA were calculated using a computer software program (FatScan, N2system, 
Osaka, Japan). Systolic and diastolic blood pressure (SBP and DBP) were measured with a 
sphygmomanometer, while maximal oxygen uptake (VO2max) was determined during a graded 
exercise test using a cycle ergometer (828E, Monark, Stockholm, Sweden). Following a two-minute 
5 
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warm-up, subjects started with a workload of 30 watts, which was increased by 15 watts each minute 
until volitional exhaustion occurred. Pulmonary ventilation and gas exchange were measured 
breath-by-breath with an on-line data acquisition system (Oxycon alpha System, Mijnhardt, Breda, 
Netherlands).  
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2.4. Blood analyses 
A blood sample was drawn from each subject after a 12-hour fast. Serum glucose and lipids 
were assayed by routine automated laboratory methods while hemoglobin A1c was measured by 
ion-exchange high performance liquid chromatography (HPLC) methods (Bio-Rad Inc, California, 
USA). Insulin was measured by an enzyme immunoassay method (Tosoh, Tokyo, Japan), and high 
sensitive CRP was measured by particle-enhanced immunoturbidimetric assay (Roche Diagnostics, 
GmbH, Mannheim, Germany). Concentrations of serum LOX-1 were measured by a sandwich 
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chemiluminescent ELISA using two different human LOX-1-specific monoclonal antibodies with a 
recombinant human LOX-1 extracellular domain as an assay standard, which was modified from the 
previously described sandwich ELISA [19]. Monoclonal antibodies directed to human LOX-1 were 
established by standard hybridoma techniques after immunizing mice with a recombinant protein 
corresponding to the extracellular domain of human LOX-1. The serum leptin, tumor necrosis factor 
(TNF)-α, and interleukin (IL)-6 levels were measured with an ELISA kit (R&D systems, 
Minneapolis, USA). The serum adiponectin levels ware measured with an ELISA kit (Otsuka 
pharmaceutical Co, Ltd, Tokyo, Japan). Intra- and inter-assay coefficients of variation (CVs) were 
4.1% and 7.6% for LOX-1, 2.8% and 3.2% for leptin, 11.8% and 6.2% for TNF-α, and 7.3% and 
3.5% for IL-6, 2.2% and 1.8% for adiponectin, respectively (n = 32). 
5 
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2.5. Statistical analysis 
Data were presented as mean ± standard deviation, and paired t tests were used to assess 
differences between variables before and after the weight reduction program. Relationships between 
two measurement variables were assessed by Pearson’s product moment correlation, while stepwise 
multiple regression analyses were used to estimate the independent contribution of the selected 
variables to the change in sLOX-1 concentration in response to weight reduction. A value of P < 
0.05 was considered to be statistically significant. All analyses were performed using SPSS software 
version 11.5 J for Windows (SPSS, Chicago, IL).  
5 
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3. Results 
Attendance at this intervention (36 sessions) averaged 80% (range 50%–100%) for the subjects. 
The frequency of the exercise program was 2.4 ± 0.6 days/week with an average duration of 95 ± 27 
min/week.  
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As shown in Table 1, body weight, BMI, fat mass, % fat mass, serum lipid, and visceral fat 
decreased significantly and maximal oxygen uptake (VO2max) increased significantly. With the 
change in weight, serum sLOX-1 level decreased 72.1% ± 35.9%. There were only two subjects with 
slight increases in serum sLOX-1 level (Δ 1.1pg/ml, Δ 6.6 pg/ml) while showing decreases in weight 
(Δ -10.3%, Δ -5.4%), fat mass (Δ -3.8%, Δ -11.0%), and visceral fat area (Δ -43.8%, Δ-30.4%) (Fig 
1A, B). 
As shown in Table 2, baseline serum sLOX-1 was positively correlated with baseline body 
weight (r = 0.473, P = 0.01) and BMI (r = 0.453, P = 0.02). Changes in sLOX-1 correlated positively 
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with changes in body weight (r = 0.542, P = 0.003), BMI (r = 0.574, P = 0.001), and fat mass (r = 
0.570, P = 0.002). No significant correlations were seen with fasting glycemic related factors (blood 
glucose, hemoglobin A1c, insulin) and VO2max at baseline or with changes. Correlations changes 
sLOX-1 with changes BMI (r = 0.437, P = 0.023) and fat mass (r = 0.462, P = 0.015 ) were 
significant even after adjustment for body weight.  5 
10 
High sensitive CRP, TNF-α, IL-6, leptin, and adiponectin decreased significantly (Table 1). 
Baseline sLOX-1 was positively correlated with baseline hsCRP (r = 0.58, P = 0.001), while changes 
in sLOX-1 correlated positively with hsCRP (r = 0.56, P = 0.002). These associations remained 
significant after adjustment body weight. Changes in sLOX-1 correlated positively with leptin (r = 
0.47, P = 0.01), and TNF-α (r = 0.32, P = 0.09) (Table 2). Stepwise multiple regression analysis 
indicated that changes in BMI and hsCRP were significant predictors of change in sLOX-1 (R2 = 
0.459), as shown in Table 3.   
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4. Discussion 
Proteolytic cleavage of LOX-1 releases a soluble form of the receptor. Since the level of soluble 
receptors in circulating blood may reflect expression of membrane proteins and disease activities, 
sLOX-1 may be a potential biomarker of vascular disease and acute coronary syndrome [20,21]. 
Brinkly et al. [22] have reported that LOX-1polymorphisms may be associated with plasma sLOX-1 
levels.  
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In the current study, the following three findings were obtained. First, serum sLOX-1 levels 
decreased significantly with weight reduction. Second, basal serum sLOX-1 levels correlated 
positively with basal body weight and BMI. Changes in serum sLOX levels correlated positively 
with changes in body weight, BMI, fat mass, abdominal fat area, and serum lipid, but no significant 
correlations were observed with glycemic related factors and VO2max. Third, changes in sLOX-1 
levels were positively correlated with changes in hsCRP and leptin. They were also marginally 
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correlated with TNF-α, whereas no correlations were observed with IL-6. Changes in BMI and 
hsCRP were significant predictors for change in sLOX-1 concentration. 
According to our observations, weight reduction contributed not only to lowering circulating 
sLOX-1 levels but also to reducing fat mass, abdominal fat area, and serum lipids, all of which are 
well-known risk factors for vascular disease. Changes in sLOX-1 levels were also significantly 
correlated with changes in the factors mentioned above. These results suggest that LOX-1 expression 
may be related to adipocyte metabolism. Brinkley et al. [23] reported that plasma levels of sLOX-1 
were significantly correlated with body weight, BMI, and total body fat. While their study may be 
the first to report an interaction between serum sLOX-1 levels and obesity, it supports our data here.  
5 
10 Obesity is also associated with alterations in immune function, but the effect of obesity itself on 
immune system function is variable [24]. Obese subjects seem to primarily have impairment in 
immune response that is reversible with weight reduction [14,15]. Serum sLOX-1 level increased 
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because LOX-1 can be induced by proinflammatory stimuli [11,25]. Indeed, Honjo et al. [26] found 
that LOX-1 is involved in endotoxin-induced inflammation as well as leukocyte recruitment and 
infiltration in vivo, and these studies suggest that LOX-1 plays a role in inflammation and immune 
response. Our observations indicated that hsCRP, TNF-α, IL6, and leptin were significantly reduced, 
as was sLOX-1, and changes in sLOX-1 were correlated with hsCRP and TNF-α. From these results, 
we speculate that inflammatory conditions were ameliorated by weight reduction. It follows that 
circulating sLOX-1 decreased. LOX-1 induction may therefore be associated with inflammation and 
immune response.  
5 
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Recent reports [27-29] indicate that the basal expression of LOX-1 in endothelial cells is very 
low. However, it can be rapidly induced by pro-inflammatory, pro-oxidant, and mechanical stimuli 
such as oxLDL [27], TNF-α [25], hsCRP [28], and shear stress [29]. LOX-1 binding to oxLDL 
rapidly elevates reactive oxygen species (ROS) levels including superoxide anion and hydrogen 
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peroxide via a membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. 
ROS can activate two signal transduction pathways involving either P38 mitogen-activated protein 
kinase (MAPK) or phosphoinositide 3-kinase (PI3K), with both causing nuclear factor-kappa B 
(NF-κB) activation and enabling nuclear translocation and subsequent regulation of 
pro-inflammatory gene expression [30-33]. According to our study, in which changes in serum 
sLOX-1 levels were correlated with hsCRP and TNF-α, circulating sLOX-1 levels may be the result 
of hsCRP and TNF-α activating LOX-1 via the NF-κB system. Two subjects showed slight increases 
in serum sLOX-1 levels, and their basal levels of sLOX-1 (7.1pg/ml, 11.0pg/ml), hsCRP (0.5mg/L, 
0.7mg/L), and TNF-α (0.1pg/ml, 0.2pg/ml) were very low. Thus, these data may support this 
phenomenon.   
5 
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Two limitations of this study were the small sample size and the fact that subjects were 
comprised solely of middle- aged Japanese men. Future research should therefore make use of a 
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wider range of subjects in terms of age, gender, and race. Nevertheless, this is the first study to 
examine whether serum sLOX-1 level can be related to weight reduction in over-weight individuals. 
Further studies are needed to clarify the clinical evidence for sLOX-1 being useful as an early 
biomarker for ACS.  
5 In conclusion, serum sLOX-1 level was significantly reduced via weight reduction intervention 
in middle-aged men. It was also significantly correlated with changes in BMI, fat mass, abdominal 
fat area, serum lipids, leptin, hsCRP, and TNF-α. These results suggest that LOX-1 induction may be 
related to adipocyte metabolism, inflammation, and immune response.  
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Figure Legends 
Comparison of changes in serum LOX-1 levels with changes in fat mass (FM) and high sensitive 
CRP (hsCRP) by simple linear regression analyses (n = 32). A) shows Δ sLOX-1 vs. ΔFM  B) 
shows Δ sLOX-1 vs. ΔhsCRP. Serum sLOX-1 showed significant correlation with fat mass (r = 
0.570, P = 0.002) and hsCRP (r = 0.564, P = 0.002). Only two subjects showed slight increases in 
serum sLOX-1 levels.   
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Table 1 
Subject characteristics at baseline and changes in measurements (n = 32) 
percent change
Age (years) 50.3 ± 12.4
Body weight (kg) 75.4 ± 6.4 -7.5 ± 4.8 -9.9 ± 5.8 ***
Body mass index (kg/m2) 26.8 ± 2.2 -2.6 ± 1.7 -9.7 ± 6.0 ***
Fat mass (kg) 18.9 ± 4.0 -3.6 ± 2.9 -19.0 ± 15.6 ***
% Fat mass (%) 25.1 ± 4.6 -2.7 ± 2.8 -11.0 ± 12.8 ***
Visceral fat area (cm2) 168.1 ± 57.7 -57.2 ± 44.7 -34.2 ± 23.8 ***
Subcutaneous fat area (cm2) 182.4 ± 56.9 -64.9 ± 37.6 -35.6 ± 18.1 ***
Total fat area (cm2) 350.4 ± 89.8 -122.1 ± 77.3 -34.2 ± 19.5 ***
Systolic blood pressure (mmHg) 131.1 ± 26.8 -9.3 ± 11.3 -6.5 ± 8.3 ***
Diastolic blood pressure (mmHg) 80.9 ± 17.5 -5.8 ± 8.6 -6.3 ± 10 ***
TC (mg/dL) 216.2 ± 41.0 -13.5 ± 28.6 -6.2 ± 12.6 *
HDLC (mg/dL) 55.6 ± 10.4 6.2 ± 10.1 11.2 ± 23.5 **
LDLC (mg/dL) 134.0 ± 35.6 -10.8 ± 23.9 -8.1 ± 16.2 *
Triglycerides (mg/dL) 132.2 ± 55.6 -44.8 ± 56.9 -33.8 ± 48.9 ***
Fasting glucose (mg/dL) 96.1 ± 21.5 -2.3 ± 12 -1.2 ± 13.1
Insulin (μU/mL) 11.3 ± 2.7 -0.9 ± 6.1 -8.0 ± 14.6
hemoglobin A1c (%) 5.3 ± 1.1 -0.3 ± 0.5 -4.3 ± 7.9 **
Maximal oxygen uptake (ml/kg/min) 29.3 ± 6.7 2.7 ± 4.6 9.6 ± 16.6 **
sLOX-1 (pg/ml) 33.8 ± 24.7 -24.3 ± 23.2 -72.1 ± 35.9 ***
high senstive CRP (mg/L) 1.4 ± 1.8 -0.5 ± 1.7 -34.5 ± 110.0 *
TNF-α (pg/ml) 0.7 ± 0.2 -0.1 ± 0.2 -10.1 ± 29.0 *
Interleukin-6 (pg/ml) 2.2 ± 1.5 -0.7 ± 1.5 -7.6 ± 76.3 **
Leptin (ng/ml) 6.5 ± 4.4 -3.7 ± 4.0 -57.4 ± 4.8 **
adiponectin (μｇ/ml) 4.1 ± 1.5 1.8 ± 1.7 43.9 ± 40.8 ***
baseline change
 
Data are mean ± SD. Percent change = change / baseline × 100. TC, total cholesterol; HDLC, high density     
5 
10 
lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; sLOX-1, soluble lectin-like oxidized     
low-density lipoprotein receptor-1; CRP, C-reactive protein; TNF, tumor necrosis factor. 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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Table 2 
Correlation coefficients at baseline and changes in sLOX-1 (n = 32) 
baseline change
Body weight (kg) r = 0.473 * r = 0.542 **
Body mass index (kg/m2) r = 0.453 * r = 0.574 ***
Fat mass (kg) r = 0.343 r = 0.570 **
Visceral fat area (cm2) r =- 0.135 r = 0.252
Subcutaneous fat area (cm2) r = 0.319 r = 0.498 **
TC (mg/dL) r = 0.275 r = 0.405 *
Triglycerides (mg/dL) r = 0.361 r = 0.219
HDLC (mg/dL) r = -0.213 r = -0.254
LDLC (mg/dL) r = 0.276 r = 0.489 **
Fasting glucose (mg/dL) r = -0.328 r = 0.097
hemoglobin A1c (%) r = -0.281 r = 0.022
Maximal oxygen uptake (ml/kg/min) r = 0.053 r = -0.129
high senstive CRP (mg/L) r = 0.575 *** r = 0.564 **
TNF-α (pg/ml) r = 0.263 r =0.321
Interleukin-6 (pg/ml) r = 0.146 r = 0.196
Leptin (ng/ml) r = 0.421 * r = 0.468 *
adiponectin (μｇ/ml) r = -0.177 r = 0.176  
TC, total cholesterol; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol;  
5 sLOX-1, soluble lectin-like oxidized low-density lipoprotein receptor-1;  
CRP, C-reactive protein; TNF, tumor necrosis factor. 
*P < 0.05, **P < 0.01, ***P < 0.001. 
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Table 3 
Stepwise multiple regression analysis for change in sLOX-1 (n= 32) 
Independent variable Beta P Change in R2 (%)
Δ BMI 0.574 0.001 30.4
ΔhsCRP 0.128 0.006 15.5  
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Figure 1  
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